[{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New study identifies drugs that are safe to use in COVID-19 treatment\r\n","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kings College London"},{"orgOrder":0,"company":"Kings College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kings College London Launches Trial Investigating the Effectiveness of Ibuprofen in COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Kings College London"},{"orgOrder":0,"company":"Imperial College London","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arthritis Drugs May Reduce Mortality and Time in ICU for Sickest Covid Patients- Reports Imperial College","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Imperial College London"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Shingrix Data Demonstrate 100% Vaccine Efficacy in the Prevention of Shingles in Adults Aged 50 and Over in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"GSK"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Shingrix (recombinant zoster vaccine – RZV) is a non-live, recombinant sub-unit vaccine indicated for the prevention of herpes zoster (HZ) in adults aged 50 and over.
Lead Product(s):Guaifenesin,Adjuvanted Recombinant Zoster Vaccine
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent. The findings come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).
Trial to evaluate formulation of ibuprofen treatment for treating severe acute respiratory distress syndrome (ARDS), a complication of COVID-19, has launched in south London.
Study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.